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1  |  INTRODUC TION
Atopic eczema (AE) or atopic dermatitis (AD) is an inflammatory skin 
disease with involvement of genetic, immunological and environ-
mental factors which are highly interconnected.1,2 The heterogenic 
disease can be separated into different phenotypes and clinical pre-
sentations defined by the ethnicity, disease onset, disease sever-
ity, chronic vs acute, intrinsic vs extrinsic (IgE level), paediatric vs 
adult and inflammatory signature.3- 5 A common feature of all sub-
types is a tremendous psychosocial burden for all patients with AE.6 
Prevalence varies by area and is reported to be 15– 20% in children 
in Europe, persisting in up to 5– 10% of adults.7- 9 Although severe 
cases are less abundant than mild or moderate disease pattern, 2% 
of affected children are severely suffering.7,9 Therefore, AE remains 
to be a high and even increasing socio- economic burden in the 
United States and in Europe,10,11 whereas slightly decreasing num-
bers were reported over the last few years in Japan.12 Children often 
overcome atopic eczema, but set off on the so- called ‘atopic march’, 
that is begin a classic ‘allergy career’. Scientifically, AE is a risk factor 
for the development of allergies. These are primarily type I allergies 
with clinical features such as hay fever and asthma. Allergies are in-
creasingly becoming a widespread disease. Currently, almost every 
fourth person in Europe suffers from symptoms such as asthma or 
hay fever and the associated restrictions in everyday life or at work. 
For society, the reduced ability to perform at school, university and 
at work means great socio- economic damage.13,14
2  |  ATOPIC EC ZEMA A S AN 
ENVIRONMENTAL DISE A SE
The picture of the reasons for the rapid increase in allergies and at-
opic diseases remains incomplete to this day. For sure, it cannot be 
explained by genetics alone.15 In fact, AE can potentially be seen as an 
environmental disease occurring in susceptible individuals.16- 18 A va-
riety of intrinsic and extrinsic risk factors were identified to influence 
Received: 16 July 2021  | Revised: 3 May 2021  | Accepted: 12 August 2021
DOI: 10.1111/all.15058  
R E V I E W  A R T I C L E
A new era of atopic eczema research: Advances and highlights
Claudia Hülpüsch1,2,3  |   Andreas B. Weins4  |   Claudia Traidl- Hoffmann1,2,3,5  |   
Matthias Reiger1,2,3
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
1Department of Environmental Medicine, 
Faculty of Medicine, University of 
Augsburg, Augsburg, Germany
2Institute of Environmental Medicine, 
Helmholtz Zentrum München, Augsburg, 
Germany
3CK CARE – Christine Kühne Center for 
Allergy research and Education, Davos, 
Switzerland
4Department of Dermatology, Faculty 
of Medicine, University of Augsburg, 
Augsburg, Germany
5ZIEL, Technical University of Munich, 
Freising, Germany
Correspondence
Claudia Traidl- Hoffmann, Department 
of Environmental Medicine, Faculty of 
Medicine, University of Augsburg, and 
Helmholtz Zentrum München, Neusäßer 




Atopic eczema (AE) is an inflammatory skin disease with involvement of genetic, im-
munological and environmental factors. One hallmark of AE is a skin barrier disruption 
on multiple, highly interconnected levels: filaggrin mutations, increased skin pH and a 
microbiome dysbiosis towards Staphylococcus aureus overgrowth are observed in ad-
dition to an abnormal type 2 immune response. Extrinsic factors seem to play a major 
role in the development of AE. As AE is a first step in the atopic march, its prevention 
and appropriate treatment are essential. Although standard therapy remains topical 
treatment, powerful systemic treatment options emerged in the last years. However, 
thorough endotyping of the individual patients is still required for ideal precision med-
icine approaches in future. Therefore, novel microbial and immunological biomarkers 
were described recently for the prediction of disease development and treatment 
response. This review summarizes the current state of the art in AE research.
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AE development and exacerbation (Figure 1).19 Intrinsic risk factors for 
AE include parental atopic history, filaggrin (FLG) mutations, polysen-
sitization, decreased short- chain fatty acids in the gut of children, and 
underlying medical conditions as keratoconus.20- 25 However, extrinsic 
factors as low microbial exposure and diversity, antibiotic exposure, 
urban environment, tobacco smoke exposure, stress, food and pollut-
ants are as important for AE development.16 The lower and later expo-
sure to microbes is described by the ‘hygiene’ or ‘old friends’ hypothesis 
and is associated with increased allergy prevalence.26- 28 The relation-
ship between host and microbes is symbiotic and bacteria shape es-
sential biological functions such as the development of a tolerogenic 
immune response towards commensals.29 In line, the prevalence of AE 
was reported to be higher in urban than in rural areas.30 The hygiene 
theory could be supported recently in a birth cohort— siblings, infec-
tions and pet— especially dog keeping— were protective for AE.28,31 
However, contradicting results exist on the influence of dog and cat 
ownership on disease development.32,33 Also, caesarean section birth 
with lower microbial exposure could recently not be confirmed to have 
a higher risk for AE than vaginal delivery,34 whereas very preterm 
birth even seems to be associated with decreased risk for AE develop-
ment.20,21 A deeper understanding of the complex interplay between 
microbes and host is still needed.35 Another environmental factor is 
the surrounding climate in a given location, a combination of temper-
ature, and precipitation and therefore UV exposure and humidity.16 
Although contradicting reports exist on the influence of the single 
factors on AE development and exacerbation, they seem to be worth 
further investigation, especially in times of climate change.16,36 These 
factors also influence sweat production, which promotes itch in AE.37 
Also, water hardness and detergent usage impact AE.9,38 The patient's 
residence also determines the exposure to airborne trigger factors as 
aeroallergens and air pollutants which are associated with AE devel-
opment and exacerbation. Especially, aeroallergens from house dust 
mite, pollen and pet dander caused positive patch tests and delayed 
cutaneous response in AE patients to a higher extent than in healthy 
controls.39 One major component of environmental air pollutants is 
Diesel exhaust particles, which triggers an itch- scratch response by 
binding to the aryl hydrocarbon receptor (AhR).40- 42 Children seem 
to be more vulnerable than adults to pollution as an AE exacerbation 
trigger.43 The stress level coming from the psychosocial environment 
is another extrinsic factor, which is correlated with disease symptom 
severity and exacerbation,6 leading to a vicious circle as AE is a strong 
psychological burden for patients.44,45 In line, psychological interven-
tions had a positive effect on AE severity in a meta- analysis and were 
also associated with other allergic diseases.46,47
3  |  ATOPIC MARCH AND DISE A SE 
PERSISTENCE
Not in all cases of childhood AE, the disease persists to adulthood. 
Risk factors for persistence are predicted by disease severity and vas-
cular endothelial growth factor (VEGF) serum levels at three years4 as 
well as by early- onset and high IL- 13 levels.48,49 Furthermore, the risk 
to develop allergic rhinitis— especially in untreated AE49— or adult- 
onset asthma is significantly higher in patients with allergic diseases 
and AE.50 Therefore, AE is claimed to be the first step of the so- called 
atopic march.51 Underlying skin barrier defects in AE facilitate the 
penetration of allergens and irritants and can thereby lead to food 
allergy, allergic rhinitis, and/or allergic asthma.13 A signature of eight 
genes (CLC, EMR4P, IL5RA, FRRS1, HRH4, SLC29A1, SIGLEC8 and 
IL1RL1) identifies multimorbidity for asthma, rhinitis and AE, suggest-
ing that multimorbidity is mechanistically different to single allergic 
diseases.52 The fact that AE itself is a risk factor for the development 
of allergies also means that the treatment of this chronic inflamma-
tory skin disease can be a prevention of other atopic diseases.
4  |  BA SIC MECHANISMS AND POTENTIAL 
TARGETS
4.1  |  Disturbed skin barrier (FLG, pH, microbiome)
The skin barrier in AE is disturbed on multiple levels, including physi-
cal, chemical, immunological, neurologic and microbial components.1
Martin et al. recently summarized genetic risk factors for AE, 
many of them belonging to extracellular matrix components and its 
modulators (eg FLG, COL5A3, COL6A6 and MMP9, TMEM79).53,54 
A variety of AE mice models are used to investigate skin barrier de-
fects, among them FLG flaky tail (ft)/ft mice,55 Hrnr−/− mice56 and 
Milestones
• Environmental risk factors are important in AE 
development
• Recognition of the complex interplay between environ-
ment and host- microbe
• Discovery of biomarkers as TARC and the microbiome 
for AE progression
• Biologics strongly improve symptom severity
• Recognition of the disease diversity is reflected in the 
variety of novel therapy targets
Outlook
• Targeting S. aureus or its communication system as lev-
erage point for local AE treatment
• S. aureus vaccines could improve the patient situation
• Efficacy of AE prevention, for example with emollients 
and pre- and probiotics is still controversial but could be 
an essential tool to stop the atopic march
• Investigation of active modulation of the skin barrier (eg 
pH) and the immune system (eg Vitamin D3, sport, food) 
should be in focus
• Time frame and trigger factors for AE development 
must be further investigated
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TMEM79−/− mice.54 One major genetic predisposition for the devel-
opment of AE are loss- of- function mutations in the skin barrier gene 
filaggrin.57 Degradation products of histidine- rich filaggrin support 
the healthy skin barrier as natural moisturizing factors (NMF) and si-
multaneously maintain an acidic skin pH.58 The skin pH in AE and es-
pecially AE lesions was reported to be increased.59 In line, an acidic 
skin pH is associated with low scaling and high hydration, whereas 
alkaline skin pH is associated with skin barrier dysfunction and de-
creased stratum corneum integrity.60,61 Alkalization of the skin pH 
directly modulates the activity of the stratum corneum located ser-
ine protease kallikrein 5 (KLK5) which has the ability to degrade cell 
junction proteins, leading to barrier dysfunction and itch.62 Recently, 
exogenic mutations in the KLK5 inhibitor Lympho- epithelial Kazal- 
type- related inhibitor (LEKTI) were associated with AE, supporting 
the importance of protease activity in the disease.63 Furthermore, 
the lipid composition of the skin is abnormal in AE. Changes in cera-
mides and free fatty acids were reported, the latter correlating with 
the skin microbiome composition.64,65
A skin microbiome dysbiosis towards Staphylococcus aureus and 
decreased microbial diversity is another hallmark of AE.66 The intrin-
sic and extrinsic factors shaping the skin microbiome are complex 
and yet poorly understood.35 However, several factors relevant in 
AE are known to influence the microbiome. The acidic skin pH of 
healthy skin for example limits the growth of harmful skin bacte-
ria as S. aureus and enhances the growth of the commensal S. epi-
dermidis.67,68 Genetics also shape the skin microbiome as recently 
shown in a mouse model: wild- type and Flg ft/ft mice significantly 
differed in the skin microbiome composition, revealing less diver-
sity with an increased staphylococci colonization.55 In this study, AE 
did not develop under germ- free conditions but was dependent on 
microbial colonization and subsequent IL- 1beta induction.55 Both 
alpha- diversity and S. aureus abundance correlate with disease se-
verity. However, this association seems to depend on the skin site 
and could be shown for the thigh but not the back of AE patients in 
a recent study.69 Not only the presence of S. aureus but also capa-
bility of S. aureus strains to produce biofilm and toxins is associated 
F I G U R E  1  Risk and protective factor for atopic dermatitis. Known extrinsic risk factors (red) and protective factors (blue) for atopic 
dermatitis are summarized in this figure
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with AE severity.66,70,71 S. aureus activates the immune system in AE 
among others by the expression of proteases, toxins, superantigens 
and other virulence factors66,72 (Figure 2). Interestingly, cigarette 
smoke redirects S. aureus towards virulence factor associated with 
persisting infection and could therefore explain the avoidable risk 
factor of tobacco smoke for AE.25,73 The virulence factors trigger a 
vicious cycle in AE. The stimulation of the immune system shapes the 
inflammatory environment, the expression of IL- 31 causes itch and 
the resulting scratching further damages the skin barrier. The com-
plex interaction between S. aureus and the innate and adaptive im-
mune system has been nicely summarized by Yoshikawa et al 2019.66
In the context of itch and scratch response, sensory neurons are 
important.74 However, the nervous system is not only responsible 
for pruritus, but also modulates the immune response in AE.75
4.2  |  Immune system
The disturbed skin barrier in AE facilitates the entrance of aller-
gens which are presented by antigen- presenting cells in the lymph 
nodes to naïve T cells, which in the presence of, for example, thymic 
stromal lymphopoietin (TSLP) differentiate into allergen- specific 
T- helper cells. These cells release IL- 4, IL- 13 and IL- 5— a major hall-
mark in AE— which lead to even stronger epithelial skin barrier dis-
ruption by downregulation of filaggrin and claudins and recruitment 
of eosinophils.76- 79 Recently, vitamin D3 was found to directly in-
fluence skin dendritic cells to drive Th2 response independently of 
thymic stromal lymphopoietin.80 Basophils were identified as one of 
the main producer of IL- 4 identified in mice and are consequently a 
potential therapeutic target.81 In turn, in vitro stimulation of eosino-
phils with IL- 4 and IL- 13 lead to an overexpression of the histamine- 
receptor H4R whose antagonists are already in clinical trials for 
AE.82- 84 Eosinophils, mast cells, dermal dendritic cells, natural killer 
cells and macrophages were found in significantly higher numbers in 
biopsies from lesional AE skin.85
The innate immune system of the skin consisting of biochemi-
cal and cellular components is the first line of defence and senses 
and regulates the skin microbiome.2,86 Multiple mutations in 
the innate immune system pathways (eg ADAM33, MIF, MMP9, 
ORM2, RETN and TLR2),53 as well as a lack of antimicrobial pep-
tides (AMPs) were reported in the context of AE. The AMPs LL- 
37, human beta- defensin- 2 (hBD- 2) and hBD- 3 are downregulated 
in AE skin lesions compared to psoriasis lesions.87,88 A deficiency 
of antimicrobial peptides in the sweat of AE patients correlates 
with an impaired innate defence in AE.89 Interestingly, AMPs are 
not only produced by the skin itself, but also by microbes.90 Not 
only AMPs but also pattern recognition receptors like Toll- like re-
ceptors (TLRs) reveal polymorphisms and aberrant expressions in 
AE, among them TLR2, which is capable of sensing Gram- positive 
staphylococci as S. aureus and TLR9.91,92 Interestingly, TLR2, which 
has been associated with severe forms of AE, can both lead to am-
plification of cutaneous inflammation and severe immunosuppres-
sion in combination with TLR6.93 S. aureus strains of AE patients 
but not laboratory strains were reported to accumulate in kerati-
nocytes and induce IL- 1alpha via TLR9,94 further exacerbating the 
inflammation. It has been shown that different staphylococcal an-
tigens cause individual response on the specific IgG and IgA pro-
duction,95 but also interactions between IgE and staphylococcal 
antigens like SEA, SEB or fibronectin have been reported to play a 
role in disease development by activating specific IgE- and T cell– 
mediated immune responses.96,97 In addition, it is also known that 
S. aureus can evade the T cell– mediated response at different steps 
and evades immunological memory which may have implications 
on vaccine development.98
F I G U R E  2  Leverage points for (future) atopic dermatitis therapies. In atopic dermatitis, the skin barrier is disturbed on multiple levels 
and could be used for atopic dermatitis treatments in future. AMP, Antimicrobial peptides; IL, Interleukin; miRNA, micro RNA; NMF, Natural 
moisturizing Factors; Th2, T- helper 2 TLR, Toll- like receptor
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5  |  DIAGNOSIS AND CLINIC AL 
A SSESSMENT OF SE VERIT Y
The American Academy of Dermatology (AAD) developed consen-
sus criteria for clinicians for the diagnosis of AE especially in young 
children consisting of three sub- categories of essential, important 
and associated features.99 Novel biomarkers to distinguish early in 
life between AE and hyper IgE syndrome (HIES) were recently re-
ported, specifically, an upregulation of CXCL10 and TNF- α and a 
downregulation of EGF for HIES compared to AE patients.100 AE se-
verity (from mild to severe) can be elucidated by validated scores like 
Scoring atopic dermatitis (SCORAD) or Eczema Area and Severity 
Index (EASI) which are useful for clinical trials.101 For daily assess-
ment of treatment success, the novel and quick to fill atopic derma-
titis score 7 (ADS7) has been proposed, which considers lesions and 
discomfort as itch and quality of life.102
6  |  BIOMARKERS FOR DISE A SE SE VERIT Y
Multiple factors have been described to correlate with AE severity. 
Measurement of NMFs via Raman spectroscopy has been shown to 
be a reliable clinical marker for AE and can be used when deciding 
for treatment.103 To objectively measure skin integrity, electrical 
impedance spectroscopy (EIS) measurements can be performed.104 
EIS measurements could be used to distinguish between healthy, 
AE non- lesional and lesional skin, correlated positively with disease 
severity, and correlated inversely with biomarkers associated with 
inflammation, making it a more reliable and sensitive tool for in vivo 
barrier disruption detection than transepidermal waterloss (TEWL) 
measurements.105 Also, the microbiome can be used as a marker for 
disease severity, assess risk- prone state of skin, and predict treat-
ment response in children across human populations.106 Among them 
are bacterial factors as S. aureus abundance, which has been corre-
lated with disease severity, but also as a biomarker for disease wors-
ening.67,107 However, before the skin microbiome can be widely used 
as clinical biomarker, a standardized method would be required for 
microbiome analysis.108 Also immunological factors are associated 
with disease severity, for example thymus and activation- regulated 
chemokine (TARC) detected in dried blood spots.109 A biomarker 
signature (p- EASI) based on multiple immunological biomarkers reli-
ably predicts disease severity.110,111 Local, non- invasive sampling of 
the skin would be well- tolerated and allows a thorough analysis of 
the complex interplay of the skin barrier, the immune system and 
microbes in vivo. Allergy- associated genes and gene- variants are 
now listed in the database AllergyGenDB which thus can be used for 
hypothesis generation in research.112 Thorough endotyping of AE 
patients would be very efficient and cost- effective for treatment.113 
One possible method would be tape stripping, which successfully 
revealed multiple AE markers in a current study.114 Biomarkers are 
essential for diagnosis and personalized and tailored therapy, espe-
cially in a multifaceted disease as AE.115
7  |  THER APY
AE therapy has undergone a true revolution in recent years. We 
are on the way to being spoilt for choice in deciding which systemic 
therapy to use. What remains to be seen, however, is which subtype 
of AE will respond to which new targeted drug. Tailored treatment 
strategy in AE depends on the individual patients’ age, history and 
disease severity, evaluated by assessing both objective and subjec-
tive factors.116,117 Interestingly, unique T- cell subsets and cytokine 
patterns in paediatric compared to adult AE patients urge for age- 
specific therapies.116,118 Considering the multidimensional nature of 
AE, effective disease management incorporates different pillars of 
treatment. Besides basic skin care and individual pharmacological 
approaches, patient education and self- management strategies that 
address social and environmental factors have to be included— not 
only to optimize individual outcomes, but also to reduce unneces-
sary costs associated with the management of AE.119 The knowledge 
and therapy options expand rapidly in AE and the current standards 
for diagnosis and therapy are nicely summarized by Wollenberg 
et al.120 Interestingly, a recent study has shown that patients self- 
reported disease severity seems to be correlated with treatment 
satisfaction of AE patients.121
7.1  |  Local therapy
With respect to the skin barrier dysfunction as a pathognomonic 
factor in the pathogenesis of AE, emollient therapy marks an essen-
tial element in the disease management: Application of emollients 
in adequate amount (>250g/week) and frequency (at least once, 
better twice a day; additionally, after any skin cleansing) is neces-
sary to enhance the integrity of epidermal barrier and consequently 
reduce the susceptibility for irritation and inflammation of the skin. 
Interestingly, a pilot study has recently shown greater efficacy of a 
novel trilipid cream (a 3:1:1 ratio of ceramides, cholesterol and free 
fatty acids) than a regular paraffin- based emollient considering the 
reduction of transepidermal water loss.122
Topical anti- inflammatory treatment is still the mainstay of mild- 
to- moderate forms of AE and especially acute exacerbations due to 
a reduction of pruritus and inflammation and restoration of skin bar-
rier function. Both topical corticosteroids (TCS) and calcineurin in-
hibitors (TCI) have shown to be safe and effective for reducing acute 
flares and risk of relapse if applied in an appropriate intensity and 
dosage, especially in a proactive setting (eg twice weekly usage on 
predilection areas). Concomitant use of emollients in an appropriate 
amount has proved a steroid- sparing effect.123,124 Besides their anti- 
inflammatory properties, positive cutaneous microbiome effects 
have been shown for TCS and TCI.
Promising new topical agents that inhibit key regulators of 
pro- inflammatory signals are in clinical development (eg Janus 
Kinase Inhibitors) or have been recently approved (eg selective 
Phosphodiesterase 4 Inhibitor Crisaborole) (see Table 1). Further 
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real- life studies will have to show their potential role in management 
of AE.120
In many cases, adequate control of AE can be achieved by topical 
treatment options, if applicable even in combination with photother-
apy (eg UVB and UVA- 1). However, if local therapy remains insuffi-
cient, or in case of severe or persistent disease, systemic treatment 
is indicated.
7.2  |  Skin barrier as a potential target for 
treatment— new developments
The disturbed skin barrier offers a variety of novel leverage points 
for future AE treatment. One option would be to tackle the dysbal-
anced skin microbiome with pre- and probiotics. A study achieved 
positive results by applying heat- treated Lactobacillus johnsonii NCC 
533 on AE skin.125 The topical microbiome transplant of Roseomonas 
mucosa from healthy participants to AE patients improved AE sever-
ity in a clinical I/II safety and activity trial.126 As S. aureus is one of the 
driving factors in AE, multiple strategies to control S. aureus growth 
emerged. An active reduction of S. aureus could be achieved with 
competing coagulase- negative staphylococci (CoNS) which produce 
antimicrobial peptides against S. aureus.127 Furthermore, it could be 
shown that CoNS could inhibit quorum sensing and thereby virulence 
of S. aureus.128,129 Another strategy is to shift the microenvironment 
towards unfavourable conditions for S. aureus. As acidic and alkaline 
pH seem to limit the growth of S. aureus in vitro and in vivo, acidifica-
tion of the skin could be one strategy. However, sustained acidifica-
tion of the skin was not yet successful.67,130 Therefore, more acidic 
products, well- buffered products or a more continuous application 
of the emollient could be beneficial. Dilute bleach baths also do not 
reduce S. aureus load and AE severity in vivo or in vitro.67,101,130,131 
Contrastingly, removal of S. aureus by UVB is known to be quite suc-
cessful.132 An exciting new strategy in AE management could also be 
an anti- S. aureus vaccine.133
7.3  |  Systemic therapy
For severe forms of AD or cases that do not respond adequately to 
topical treatment, systemic therapy should be considered. In practice, 
several systemic anti- inflammatory treatment options are established 
for treating AE: Until approval of dupilumab in 2017 and baricitinib 
in 2020, cyclosporine has been considered as first- line option over 
many years. Other immunosuppressive drugs (eg azathioprine, meth-
otrexate) have been also used with good response, but off label and/
or as second- line therapy, in AE.134,135 As stated above, many differ-
ent cellular and molecular effectors are involved in AE. The expand-
ing knowledge of this complex type 2 immunological background of 
AE leads to new developments of new cytokine- directed treatment 
options that are currently under investigation (Table 1).117,135- 138
The European Academy of Allergy and Clinical Immunology 
(EAACI) AE guideline group nicely summarized evidence on systemic 
treatments for AE identifying the need for trials comparing novel 
systemic treatments with conventional therapies.135
Besides skin inflammation and barrier dysfunction, itch rep-
resents a cardinal symptom of AE. For a long time, histamine has 
been assumed to be the main mediator of itch. Antihistamines 
have been commonly used for reducing itch in AE patients, but 
with conflicting evidence. Two Cochrane studies have recently 
shown that antihistamines have no or just a limited antipruritic 
effect.139,140 It is important to note that recent research has re-
sulted in progress in understanding the complex pathophysiology 
of atopic itch, from which more specific treatment options will 
arise perspectively.141
7.4  |  New developments in systemic 
treatment options
Several more biologics and small molecules interfering with key me-
diators of AE are currently in development and may contribute to tai-
lored therapeutic approaches in future.78 An interesting approach to 
improve AE in patients unresponsive to extensive therapy is, to use 
repetitive transient reductions of total IgE, which lead in a small num-
ber of patients to long- lasting improvement of AE with improvement 
of both clinical parameters as well as the quality of life.142 Allergen- 
specific immunotherapy (ASIT) is currently not recommended as a 
common treatment approach.132 But ASIT against animal dander 
has been shown to reduce specific IgE in AE patients and could 
be effective treatment option for patients with respiratory allergic 
comorbidities.143 Additionally, downregulatory strategies for the 
immune system are under investigation. CD300a expression has a 
downregulatory role in AE (mice), this could be an anti- inflammatory 
strategy.85 The immune system in epithelial cells is posttranscrip-
tional regulated by miRNAs.144 Among others, miR- 10a- 5p has been 
identified to modulate AE targets.145 L- type amino acid transporter 
1 (LAT1) is critical for activating human and mouse T cells and its 
inhibition reveals a potential new target for AE treatment.146
It is important to increase the knowledge about the complex 
mechanisms influencing AE and therefore a combination of patient 
information correlated with biomaterial analysis and in vitro testing 
is needed. The CK- CARE program will contribute to identify and val-
idate new and reliable biomarkers for precision medicine.147
8  |  PRE VENTION
As the underlying skin barrier defects observed in AE are the first 
step in the atopic march, the prevention of AE is very appealing— 
and especially in families with known risk factors— highly important. 
As emollients are the primary management strategy in AE, emol-
lient application at early age is an obvious prevention method for 
AE. Contradictory data exist on its efficiency. Whereas earlier stud-
ies hinted towards a highly effective approach for AE prevention in 
neonates, this could not be confirmed in recent studies where no 
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evidence was found that daily emollients had a preventive effect in 
neither a population- based nor a high- risk cohort.148- 153 One factor 
for the conflicting results could be the formulation of the ointment. 
Ceramide- based emollients are more efficient in reducing the TEWL, 
whereas peanut- oil based ointments were reported to be a facilita-
tor for allergy.122,154 Due to the barrier defect, emollient compo-
nents can most likely cross the skin barrier more easily in AE. Even 
though early supplementation of peanut, cow milk, wheat and eggs 
was not protective for AE,149 a diverse diet and cheese consumption 
seem to be beneficial, possibly due to the high microbial diversity 
found in cheese.155,156 In the same direction, pre- and probiotics are 
potentially protective for AE development.157 Although prebiotics 
are non- digestional ingredients which promote beneficial bacteria 
such as Bifidobacterium and Lactobacilli, probiotics are active bac-
teria which are beneficial for human health.158,159 Among them are 
Bifidobacterium and Lactobacilli, Gram- positive, anaerobic bacteria 
which are potentially capable of producing lactic- acids and antimi-
crobial substances and bacteriocins, limiting potentially pathogenic 
gut bacteria.157 The data on the efficiency of pre- and probiotics are 
highly controversial, likely due to differences in type or mixture of 
strains.160 Orally applied prebiotic Escherichia coli and Enterococcus 
faecalis in children were ineffective in AE prevention.161 Contrarily, 
the administration of probiotics during pregnancy has been con-
firmed to prevent AE of the children in a meta- analysis of 19 stud-
ies.162 Continuation of probiotics during breastfeeding and then the 
infant seemed efficient in reducing the risk of AE.160,163
9  |  HOT TOPIC— ATOPIC EC ZEMA AND 
SARS-  COV- 2
In the context of the Corona pandemic, it is of interest that especially 
one known SARS- CoV- 2 receptor, CD147 and its related molecules, 
are expressed higher in lesions of AE patients than healthy controls 
and could hint towards a predisposition towards SARS- CoV- 2 infec-
tions.164 However, allergy was not identified as risk factor for bad 
COVID- 19 outcome in children.165 Therefore, it is advised for AE 
patients to continue immune- modulating treatments.166,167 Also, 
COVID- 19 vaccinations are recommended for AE patients without 
pausing medication before or after vaccination.168
10  |  CONCLUSION
Atopic dermatitis is a complex skin disease with underlying skin 
barrier defects. Multiple intrinsic but also extrinsic factors put hu-
mans at risk to develop AE— among them environmental factors 
which in times of climate change could play an even stronger role 
in future. However, the heterogenous disease can be divided into 
multiple endotypes with different pathomechanisms. Therefore, a 
personalized medicine approach for an effective management of 
AE is needed. New strategies emerged in the last years, tackling 
the skin barrier including the microbiome or factors of the immune 
system. Even better would be the prevention of AE, possibly by 
suitable emollients or pre- and probiotics, as AE is known and con-
firmed to be the first step of the atopic march. Many parts of the 
complex disease mechanisms could be unravelled in the last dec-
ades. However, much is still unknown and must be addressed by 
the science community, particularly host- microbe and environmen-
tal interaction.
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